Content about Genentech

February 11, 2011

Genentech, a subsidiary of Roche, reported that its eye drug helped improve vision in patients suffering from a complication caused by diabetes.

SOUTH SAN FRANCISCO, Calif. — Genentech, a subsidiary of Roche, reported that its eye drug helped improve vision in patients suffering from a complication caused by diabetes.

In its phase-3 RISE study, Genentech said diabetic macular edema patients that received monthly Lucentis (ranibizumab injection) achieved an improvement in vision at 24 months, compared with placebo.

February 9, 2011

Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

SOUTH SAN FRANCISCO, Calif. — Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

Genentech, part of Swiss drug maker Roche, announced results from its phase-3 “OCEANS” study, in which women with recurring ovarian cancer received Avastin (bevacizumab) with gemcitabine and carboplatin, both chemotherapy drugs, followed by use of Avastin alone.

January 19, 2011

Drug maker Genentech is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke its approval for the disease, according to published reports.

NEW YORK — Drug maker Genentech is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke its approval for the disease, according to published reports.

The San Francisco Business Times reported Tuesday that Genentech, part of Swiss drug maker Roche, is appealing the FDA’s plan to revoke approval for the drug Avastin (bevacizumab) as a first-line treatment for advanced HER2-negative breast cancer in combination with paclitaxel chemotherapy.

January 19, 2011

Patients taking an investigational drug made by Genentech for advanced skin cancer fared better than those receiving standard treatments, according to results of a late-stage clinical trial announced Wednesday.

SOUTH SAN FRANCISCO, Calif. — Patients taking an investigational drug made by Genentech for advanced skin cancer fared better than those receiving standard treatments, according to results of a late-stage clinical trial announced Wednesday.

The company, part of Swiss drug maker Roche, said patients with advanced melanoma containing a mutated version of a protein called BRAF lived longer when receiving the orally administered personalized investigational medicine RG7204 than those receiving the injected chemotherapy drug dacarbazine.

January 18, 2011

Generic drug maker Sandoz has started a mid-stage clinical trial of a monoclonal antibody used to treat cancer and autoimmune disease, the company said.

HOLZKIRCHEN, Switzerland — Generic drug maker Sandoz has started a mid-stage clinical trial of a monoclonal antibody used to treat cancer and autoimmune disease, the company said.

Sandoz (pronounced “SAN-doh”), the generics arm of Swiss drug maker Novartis, announced the start of a phase-2 trial of rituximab, a biosimilar of Genentech’s Rituxan, used to treat such conditions as non-Hodgkin’s lymphoma and rheumatoid arthritis.

January 14, 2011

Biotech company Genentech advised consumers to avoid alcohol prep pads distributed with some of its drugs due to possible contamination.

SOUTH SAN FRANCISCO, Calif. — Biotech company Genentech advised consumers to avoid alcohol prep pads distributed with some of its drugs due to possible contamination.

Genentech, a subsidiary of Swiss drug maker Roche, said users of its drugs should not use prep pads made by Triad Group, but that the drugs themselves were still safe to use. Triad Group recently recalled several of its pads due to contamination, prompting Bayer HealthCare to issue a similar warning.

January 6, 2011

The Food and Drug Administration has expanded the approved usage of a drug made by Genentech, part of Swiss drug maker Roche.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has expanded the approved usage of a drug made by Genentech, part of Swiss drug maker Roche.

The FDA approved Actemra (tocilizumab) for the inhibition and slowing of structural joint damage, improvement of physical function and achievement of clinical response in patients with moderate to severe rheumatoid arthritis. The drug originally was approved as a treatment for RA last year.

January 6, 2011

A U.S. biotech company plans to develop a biosimilar of a monoclonal antibody used to treat cancers and autoimmune disorders.

IRVINE, Calif. — A U.S. biotech company plans to develop a biosimilar of a monoclonal antibody used to treat cancers and autoimmune disorders.

Spectrum Pharmaceuticals announced Wednesday a deal with Viropro to develop a biosimilar rituximab, marketed under the brand name Rituxan by Roche’s Genentech division. Global sales of rituximab in 2009 were $5.6 billion, according to Spectrum.

December 16, 2010

Just a few months after a Food and Drug Administration advisory committee recommended limiting the use of a Genentech drug designed to treat breast cancer, the regulatory agency is looking to revoke the approval altogether.

SILVER SPRING, Md. — Just a few months after a Food and Drug Administration advisory committee recommended limiting the use of a Genentech drug designed to treat breast cancer, the regulatory agency is looking to revoke the approval altogether.

December 15, 2010

Procter & Gamble on Tuesday afternoon named a healthcare veteran to its board. Susan Desmond-Hellmann, 53, chancellor of the University of California, San Francisco was named to the board, effective Dec. 13.

CINCINNATI — Procter & Gamble on Tuesday afternoon named a healthcare veteran to its board. Susan Desmond-Hellmann, 53, chancellor of the University of California, San Francisco, was named to the board, effective Dec. 13.

December 9, 2010

An investigational treatment for lung cancer made by Boehringer Ingelheim Pharmaceuticals extended patients’ survival by more than four months, according to results of a late-stage clinical trial announced Thursday.

RIDGEFIELD, Conn. — An investigational treatment for lung cancer made by Boehringer Ingelheim Pharmaceuticals extended patients’ survival by more than four months, according to results of a late-stage clinical trial announced Thursday.

BI said the phase 2b/3 “LUX-Lung 1” trial of BIBW 2992 (afatinib) showed a fourfold increase in survival among advanced non-small cell lung cancer patients taking the drug versus those taking placebo, whose survival was extended by one month.

December 6, 2010

A biotech drug made by Roche subsidiary Genentech allowed patients with a blood cancer, who did not show symptoms, to delay starting on chemotherapy or radiotherapy, and decreased the risk of their disease worsening, according to results of a late-stage clinical trial.

SOUTH SAN FRANCISCO, Calif. — A biotech drug made by Roche subsidiary Genentech allowed patients with a blood cancer, who did not show symptoms, to delay starting on chemotherapy or radiotherapy, and decreased the risk of their disease worsening, according to results of a late-stage clinical trial.

October 20, 2010

The Food and Drug Administration has approved a biotech drug for treating cancer of the...

SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a biotech drug for treating cancer of the stomach and esophageal junction.

 

Genentech, a subsidiary of Swiss drug maker Roche, announced Wednesday the approval of Herceptin (trastuzumab) as a treatment for cancer of the stomach that includes the HER2 gene and has spread to other parts of the body, when combined with chemotherapy. The drug has long since had approval as a treatment for HER2-positive breast cancer.

 

 

September 19, 2010

Biotech company Genentech has amended its application to the Food and Drug Administration seeking an...

SOUTH SAN FRANCISCO, Calif. Biotech company Genentech has amended its application to the Food and Drug Administration seeking an additional approval for one of its drugs, which the FDA has deemed a “major amendment,” Genentech said Monday.

 

September 8, 2010

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial...

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial of a biotech drug for treating cancer, the two companies said.

 

August 26, 2010

Pfizer reported mixed results this week in a late-stage clinical trial combining two drugs in...

NEW YORK Pfizer reported mixed results this week in a late-stage clinical trial combining two drugs in patients with advanced non-small cell lung cancer.

The drug maker said the combination of Pfizer’s Sutent (sunitinib) and Tarceva (erlotinib), made by Genentech and OSI Pharmaceuticals, kept the disease from progressing, but did not improve patients’ overall survival, which was the trial’s primary goal. The company expects to present results at the European Society for Medical Oncology Congress in Milan in October.

July 20, 2010

A Food and Drug Administration advisory committee has voted to recommend limiting use of a...

June 22, 2010

The Food and Drug Administration has approved a drug made by Genentech for treating a...

June 15, 2010

Drug maker OXiGENE has finished enrolling patients for a mid-stage clinical trial of a lung...

June 9, 2010

Bayer HealthCare Pharmaceuticals trade relations director Michael Catanio received the Nexus Award for Lifetime Achievement...

June 7, 2010

Japanese drug maker Astellas Pharma has completed its acquisition of OSI Pharmaceuticals, Astellas said Tuesday....

May 18, 2010

The Food and Drug Administration has approved a new biotech drug made by Roche U.S....

May 16, 2010

Japanese drug maker Astellas Pharma will acquire U.S.-based OSI Pharmaceuticals for $4 billion, the two...

May 16, 2010

Sandoz got its hands on a collection of generic drug candidates as it agreed to...

May 9, 2010

U.S. biotechnology company Genentech and German drug maker Evotec hope to develop drugs using Evotec’s...